key: cord-0924627-it3duk4j
authors: Le Cleach, L.; Dousset, L.; Assier, H.; Fourati, S.; Barbarot, S.; Boulard, C.; Bourseau Quetier, C.; Cambon, L.; Cazanave, C.; Colin, A.; Kostrzewa, E.; Lesort, C.; Levy Roy, A.; Lombart, F.; Marco‐Bonnet, J.; Monfort, J.B.; Samimi, M.; Tardieu, M.; Wolkenstein, P.; Sbidian, E.; Beylot‐Barry, M.
title: Most chilblains observed during the COVID‐19 outbreak occur in patients who are negative for COVID‐19 on PCR and serology testing
date: 2020-07-06
journal: Br J Dermatol
DOI: 10.1111/bjd.19377
sha: c8cae031617d078c43df3ea0d2bfd50ce01ad219
doc_id: 924627
cord_uid: it3duk4j

INTRODUCTION: Acral lesions, mainly chilblains, are the most frequently reported cutaneous lesions associated with COVID‐19. In more than 80% of tested patients, nasopharyngeal swabs were negative on RT‐PCR for SARS‐CoV‐2 when performed, and serology was generally not performed. MATERIALS AND METHODS: A national survey was launched on March 30, 2020 by the French society of dermatology asking physicians to report cases of skin manifestations in patients with suspected or confirmed COVID‐19 by using a standardized questionnaire. We report the results for acral manifestations. RESULTS: We collected 311 cases of acral manifestations (58.5% females, median age 25.7 years [range 18‐39]). The most frequent clinical presentation (65%) was typical chilblains. In total, 93 cases (30%) showed clinical suspicion of COVID‐19, 67 (22%) had only less specific infectious symptoms, and 151 (49%) had no clinical signs preceding or during the course of acral lesions. Histology of skin biopsies was consistent with chilblains (n= 26/29). Twelve patients showed significant immunological abnormalities. Ten patients were positive among the 150 (48%) who were tested (RT‐PCR and/or serology). Seven of 121 RT‐PCR–tested patients were positive and 5 of 75 serology‐tested patients were positive (IgG) among them RT‐PCR and serology were both positive for two patients. Seven of 121 RT‐PCR–tested patients were positive for SARS‐CoV‐2 (6%), and 5 of 75 serology‐tested patients had IgG anti‐ SARS‐CoV‐2 (7 %). Tested and untested patients or those with and without confirmed COVID‐19 did not differ in age, sex, history or acral‐lesion clinical characteristics. CONCLUSION: The results of this survey do not rule out that SARS‐CoV‐2 could be directly responsible for some cases of chilblains but found no evidence of SARS‐CoV‐2 infection in large majority of patients with acral lesions during the COVID‐19 lockdown period in France.

Coronavirus disease 2019 (COVID-19) is a disease due to SARS-CoV-2 infection that was first reported in Wuhan, China and has subsequently spread to the rest of the world. 1,2 The World Health Organization (WHO) declared a pandemic viral infection on March 11, 2020.

The first cutaneous manifestations were described in mid-March; since then, more than 50 publications reporting more than 1000 cases have been published, mainly from European countries. Cutaneous manifestations possibly associated with COVID-19 are diverse and include different types of exanthema; maculopapular, urticarial, chicken pox-like lesions. 3,4 Acral lesions, mainly chilblains, are the most frequently reported cutaneous manifestation. 5, 3 The direct causal link between these skin manifestations and SARS-CoV-2 infection is suspected but remains uncertain.

Acral lesions are mainly observed in adolescents and young adults and are clinically described as pseudo-chilblains, sometimes with bullous lesions or pseudo-erythema multiform (EM), two patterns that can overlap. Lesions resolved spontaneously in 1 to 4 weeks. 3, 6 Because of the high number of reported cases, media sources alerted that chilblains are a sign of COVID-19 and that appearance of such cutaneous manifestations should lead to measures of isolation and COVID-19 testing.

The aim of our study was to describe clinical characteristics of acral lesions at the time of the COVID-19 outbreak in order to provide evidence of an association or lack of association between SARS-CoV-2 infection and acral manifestations.

A national survey was launched on March 30, 2020 by the French society of dermatology asking physicians to report cases of skin manifestations in patients with clinically suspected or confirmed by RT-PCR and or serology COVID-19. We report here the results for acral manifestations for which the survey was closed on May 4, 2020. A standardized questionnaire was sent to society members on the mailing list and was accessible on the society website (www.sfdermato.org). In addition to completing the questionnaire,

This article is protected by copyright. All rights reserved recipients were asked to send pictures, results of biological tests including nasopharyngeal swabs for RT-PCR detection of SARS-CoV-2, serology for SARS-CoV-2 IgG detection, and histology of skin biopsies if available. For serology, serum samples were processed for 60 patients on an Abbott Architect instrument with the Abbott SARS-CoV-2 IgG assay following the manufacturer's instructions. The assay is a chemiluminescent microparticle immunoassay for qualitative detection of IgG against the SARS-

This article is protected by copyright. All rights reserved CoV-2 nucleoprotein in human serum. Qualitative results and index values reported by the instrument and associated to 99.90 % specificity and 100% sensitivity were used in analysis. 7 For the 10 other patients kit used for serology testing was not specified.

Continuous data are described with mean± SD or median (interquartile range [IQR]) depending on normal distribution or not. Categorical data are described with number (percentage). Our main analysis was descriptive, assessing characteristics of patients with acral manifestations. The characteristics of patients with and without testing and positive or negative on testing were compared by chi-square test or Fisher's exact test for categorical data and Mann-Whitney test for continuous variables. All tests were two-tailed, and the threshold for statistical significance was set to p<0·05. All statistical analyses were performed with Stata v14.1 (StataCorp LP, College Station, TX, USA).

We Overall, 93 (30%) patients had fever and/or cough and/or dyspnoea and/or anosmia-ageusia and were classified as suspected to have COVID-19; 3 had pneumonia, none was admitted to an ICU and none died. A total of 67 (22%) patients had only less specific infectious symptoms (nausea, vomiting and/or diarrhoea and/or odynophagia and/or asthenia and/or myalgia and/or headache), and 151 (49%) had no clinical signs preceding or during the course of acral lesions. In most cases, no specific treatment was applied, and topical corticosteroids were prescribed for 54 (17%) patients.

This article is protected by copyright. All rights reserved Clinical presentation was classified in 4 categories after photograph review. Classification was feasible for 245 (79%) patients for whom photographs were sent. The most frequent clinical presentation was typical chilblains (n=202/245, 82%) located mainly on the dorsum of toes. (Fig 2 a-e); 22 cases had a severe form with bullae (Fig 2c) . Other forms were EM-like lesions, mainly on the lateral part of feet (Fig 3) , in 15 (6%) patients; punctiform purpuric lesions on dorsum and/or pulps in 11 (4.5%) (Fig 4) ; and diffuse vascular erythema and oedema of dorsum or soles of feet and/or palms in 17 (7%). Table S1 )

This article is protected by copyright. All rights reserved Comparison between tested and untested patients (Table 1) Tested and untested patients did not differ in age, sex, history or acral-lesion clinical characteristics nor rate of clinically suspected COVID-19 with only non-specific symptoms and no symptoms. We observed that headache was significantly more frequent in tested patients 32% (48 /150) compared to untested patients vs 19% (30/161) p < 0.009.

Comparison between RT-PCR-and/or serology-positive and -negative patients (Table 2) Patients with and without confirmed COVID-19 did not differ in age, sex, history or acral-lesion clinical characteristics. Headache and anosmia-ageusia were significantly more frequent in confirmed with respectively 70% (7/10) and 50% (5/10) than unconfirmed cases 29% (41/140) and 8% (6/140) (p < 0.013 and 0.001).

We report 311 cases of acral lesions, mainly chilblains, occurring during the COVID-19 outbreak Table S2 ). These series came from 4 countries (Italy, Spain, France and USA). It is possible that some cases were reported in more than one series. Concerning our 311 patients, to our knowledge histological characteristics of 17 cases were already reported. 8 As in our study in which median age was 25.7 years (IQR 18-38.3), most patients reported in these previous studies, were children or young adults (mean age was between 10 to 20 years in 10 series, was 32.5 in one and median age varied from 14 to 27 in 3). Rate of patients having no general symptoms preceding or concomitant to skin lesions was 207/678 (30%), based on 10 series; data missing for the 4 other series, compared with 49% (151/311) in our study. When present symptoms were mild. Skin lesions were generally described as chilblains or pseudochilblains and more rarely EM-like lesions. Overall, 300 patients had laboratory confirmation by RT-PCR of a nasopharyngeal swab, which was positive in 54 (18%) based on 13 series. In one study, 3 the proportion was higher (41% (29/71)) than in the 12 others (11% (25/229)), varying

This article is protected by copyright. All rights reserved from 0 to 21%. By comparison the proportion of positive RT-PCR in our study in patients that were tested was 6% (7/121). Serology was rarely performed and was positive in 7/39 for IgG and 6/19 for IgA in the former series compared with 5/75 (7%) for IgG in our study. 5,3,9,10,11,12,13, 14, 15, 16, 17, 18, 19, 20 Serology was not available at the time of publication of these previous series. Also, RT-PCR negativity was considered as expected because chilblains were considered a late manifestation of the infection, occurring 1 to 5 weeks after signs of infection, with the disappearance of detectable virus after a brief or pauci-symptomatic infection in young healthy individuals, possibly due to an immunologic response targeting the cutaneous vessels. Indeed, firstly sensitivity of RT-PCR varied from 71 to 98% based on negative RT-PCR tests which were positive on repeat testing and secondly the median time from symptoms onset to negative SARS-CoV-2 RT-PCR test in hospitalized patients result was 20 days. 21, 22 Thus, it is possible that in some patients negative RT PCR in these studies could be false negative.

By contrast, the absence in our study of SARS CoV-2 IgG antibodies using a highly sensitive and specific test in 65/70 tested patients, 3 weeks (median IQR 12-30) after onset of symptoms, is a strong argument against a direct causal link between COVID-19 and chilblains. Indeed, performance assessment of the serology Abbott Architect instrument (used in 60/75 patients in our study) have found that all patients with positive Sars-CoV-2 RT-PCR had a positive serology 17 days after beginning of symptoms. In a series reporting 19 cases of chilblains in adolescent, serology were negative for IgG using the same kit we used (Abbott) and were positive for IgG in one patient and for IgA in 6 and borderline for 3 using another kit (Euroimmun). 19 The authors suggested that in children asymptomatic or with mild infection humoral response could be IgA rather than IgG . However, as Euroimmun kit is known to provide false positive results these results have to be taken with caution. 22, 23 Four studies reported frequency of cutaneous manifestations in patients with confirmed SARS-Cov-2 infection in 0.2% (total population n=1099 patients), 4.9% (total population n=103), 20.4% (total population n=88), 10% (total population n=125), and 7.8% (total population n=678). 9,24,25,18 Among these patients, only one had chilblains. However, the mean age of these patients was higher.

Lack of difference in sex, age, history of connective tissue disease, and acral lesion characteristics between patients with and without confirmed COVID-19 could also be an argument against the role of viral infection in the chilblains.

This article is protected by copyright. All rights reserved Our study has some limitations, mainly that all patients did not have the same investigation. However, the characteristics of untested patients did not significantly differ from those of tested patients. We hypothesized that these results could reasonably be extrapolated to the whole population. Photographs were not available for 66 of 311 patients, who could not be classified more precisely than having chilblains. The strengths of this survey are the large number of included patients and that almost half of the population had a test to confirm COVID-19 including a serology for 75 patients. Our study had a different methodology from the study of If chilblains are not directly related to COVID-19, how can we explain the numerous reported cases? Most reported cases occurred between March and April 2020 in southern Europe. The incidence of chilblains is not known, so affirming an increase is difficult. However, many dermatologists confirmed that this chief complaint was more frequent than in previous years. The situation could be due to the media stating that chilblains were caused by SARS-CoV-2 infection and leading to higher rate of consultation for benign cutaneous manifestations or the lockdown leading to more inactivity and long periods at home barefoot on a cold floor. For March and April,

This article is protected by copyright. All rights reserved the mean temperature was 9 degrees Celsius (range -5.8 to +25.2) and 13.7 (-6.3 to +27.1), respectively, in France. (www.terre-net.fr)

The results of this survey did not rule out that SARS-CoV-2 infection could be directly responsible for some cases of chilblains but found no evidence of SARS-CoV-2 infection in large majority of patients with acral lesions during the COVID-19 lockdown period in France. This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved *p-value from chi-square or Fisher test for categorial variables or Mann-Whitney test for continuous variables. 

COVID-19 pandemic: a retrospective nationwide study from France

Chilblain-like lesions in pediatrics dermatological outpatients during the COVID -19 outbreak

Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemic

The management of the outbreak of acral skin manifestations in asymptomatic children during COVID -19 era

Novel outbreak of acral lesions in times of COVID-19: A description of 74 cases from a tertiary university hospital in Spain

Diversity of clinical appearance of cutaneous manifestations in the course of COVID-19

A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection

Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries

Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: A descriptive study

Interpreting a covid-19 test result

immunoassays. Infectious Diseases (except HIV/AIDS)

SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies